BV

Biom Pharmaceutical Published Clinical Safety & Efficacy of VagiBiom® Microbiome-based Probiotic Suppositories for Intimate Women's Health

Retrieved on: 
Tuesday, February 27, 2024

Numerous studies suggest that a balanced vaginal microbiome is critical to long-term health and wellness.

Key Points: 
  • Numerous studies suggest that a balanced vaginal microbiome is critical to long-term health and wellness.
  • "We are excited to share the results of the VagiBIOM clinical study; the need for natural solutions in vaginal health is largely unmet.
  • The results of the current peer-reviewed published clinical trial reinforce the safety and efficacy of our product.
  • However, the current peer-reviewed clinical results further reinforce the safety and efficacy of our product,” said Biom's Founder & President, Dr. Bobban Subhadra.

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Cylus Achieves World's First IEC 62443-4-2 Certification for Rail Tech Cybersecurity Solution, Setting a New Industry Standard

Retrieved on: 
Monday, February 26, 2024

This milestone highlights Cylus's commitment to providing a comprehensive rail cybersecurity solution and establishes a new benchmark in operational rail technology security.

Key Points: 
  • This milestone highlights Cylus's commitment to providing a comprehensive rail cybersecurity solution and establishes a new benchmark in operational rail technology security.
  • The IEC 62443-4-2 standard, developed by the International Electrotechnical Commission (IEC), sets stringent cybersecurity guidelines for industrial automation and control systems (IACS).
  • The certification of the CylusOne solution has significant implications for the rail industry, offering enhanced cybersecurity, regulatory compliance, and passenger safety.
  • The certification of our CylusOne solution under IEC 62443-4-2 is a major achievement in rail cybersecurity, setting a high bar for industry practices," says Miki Shifman, Co-Founder and CTO of Cylus.

37 UBS advisor teams in Florida named to Forbes Best-In-State Wealth Management Teams list

Retrieved on: 
Tuesday, February 13, 2024

TAMPA, Fla., Feb. 13, 2024 /PRNewswire/ -- UBS Wealth Management USA announced today that 37 financial advisor teams in Florida have been named to the Forbes Best-In-State Wealth Management Teams list for 2024.

Key Points: 
  • TAMPA, Fla., Feb. 13, 2024 /PRNewswire/ -- UBS Wealth Management USA announced today that 37 financial advisor teams in Florida have been named to the Forbes Best-In-State Wealth Management Teams list for 2024.
  • The UBS wealth management teams named to the list in Florida include:
    Constellation Wealth Management : Nick Sadowsky, CPM®; Hank Boyce, CFA®; Worth Boyce, CFP®; Missy Fierman.
  • CFP®.
  • The Forbes/SHOOK Best-In-State Wealth Management Teams list for 2024 is composed of more than 4,100 teams that collectively manage approximately $5.1 trillion in client assets.

EverSmith Brands Acquires U.S. Lawns, Expanding Its Landscaping Portfolio

Retrieved on: 
Thursday, February 1, 2024

"U.S. Lawns represents an ideal fit for EverSmith Brands as we pursue our vision of building the industry-leading franchise platform for commercial property services," said EverSmith Brands' CEO, Rob Gannett, in a statement.

Key Points: 
  • "U.S. Lawns represents an ideal fit for EverSmith Brands as we pursue our vision of building the industry-leading franchise platform for commercial property services," said EverSmith Brands' CEO, Rob Gannett, in a statement.
  • U.S. Lawns joins Clintar, Canada's largest commercial landscaping and snow management franchise, in the EverSmith Brands portfolio.
  • With the acquisition, Ken Hutcheson, the current President of U.S. Lawns, is appointed as President, Landscaping and Snow Services, for EverSmith Brands.
  • EverSmith Brands, a platform of strong and growing franchised brands, and portfolio company of The Riverside Company, is uniquely focused on the commercial facilities sector including the Clintar, KitchenGuard, MilliCare, and U.S. Lawns brands.

BrightView Publishes 2024 Corporate Responsibility Report

Retrieved on: 
Friday, January 26, 2024

BrightView (NYSE: BV), the leading commercial landscaping services company in the United States, today published its 2024 Corporate Responsibility Report, highlighting the Company’s commitment to being a good corporate citizen focused on environmental stewardship, social responsibility, and corporate governance.

Key Points: 
  • BrightView (NYSE: BV), the leading commercial landscaping services company in the United States, today published its 2024 Corporate Responsibility Report, highlighting the Company’s commitment to being a good corporate citizen focused on environmental stewardship, social responsibility, and corporate governance.
  • View the full release here: https://www.businesswire.com/news/home/20240126331546/en/
    “This report reflects our team’s hard work over the past year and continued focus on corporate responsibility and sustainability initiatives.
  • Every day we set out to positively impact our stakeholders, including our employees, clients, investors, and neighbors,” said Dale Asplund, BrightView President and Chief Executive Officer.
  • Raised over $160,000, through the BrightView Landscapes Foundation, to support team members in critical situations.

BrightView Holdings, Inc. Announces First Quarter Fiscal Year 2024 Earnings Release Date, Conference Call and Webcast

Retrieved on: 
Thursday, January 18, 2024

BrightView Holdings, Inc. (NYSE: BV) will release its earnings results for the first quarter fiscal year 2024 after the market closes on Wednesday, January 31, 2024.

Key Points: 
  • BrightView Holdings, Inc. (NYSE: BV) will release its earnings results for the first quarter fiscal year 2024 after the market closes on Wednesday, January 31, 2024.
  • BrightView will hold a conference call to discuss its results the following morning, Thursday, February 1, 2024, at 8:30 a.m. EST.
  • Instructions to join the conference call are provided below:

Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert® Xpress MVP

Retrieved on: 
Thursday, January 18, 2024

SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP. This multiplex vaginal panel can now be performed in near-patient settings, enabling results within 60 minutes from a single specimen for Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis (TV). This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care. The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.

Key Points: 
  • SUNNYVALE, Calif., Jan. 18, 2024 /PRNewswire/ -- Cepheid announced today that it has received FDA Clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert® Xpress MVP.
  • This expanded claim exemplifies Cepheid's commitment to providing expanded access to women's and sexual health by making PCR testing accessible at the point of care.
  • The test runs on Cepheid's GeneXpert Xpress instruments and has been approved for testing women fourteen years of age and older.
  • For more information about Cepheid's Xpert Xpress MVP test, please visit Cepheid's website.

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Retrieved on: 
Wednesday, January 10, 2024

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced that XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription to treat bacterial vaginosis (BV).
  • Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
  • If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.
  • Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com .

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Retrieved on: 
Monday, December 11, 2023

Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.

Key Points: 
  • Affimed will host a webcast following the presentation to review the data and provide a strategic update on acimtamig’s future development.
  • A total of 42 patients were enrolled in the study with 36 patients treated at the RP2D.
  • 32 of the 36 patients treated at the RP2D were HL patients.
  • For the HL patients treated at the RP2D, median EFS was 9.8 months - with 84% patients alive at 12 months.